Compare SHASUN PHARMA with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs LUPIN - Comparison Results

LUPIN 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA LUPIN SHASUN PHARMA/
LUPIN
 
P/E (TTM) x 123.9 49.2 251.9% View Chart
P/BV x 8.5 2.5 338.3% View Chart
Dividend Yield % 0.2 0.0 -  

Financials

 SHASUN PHARMA   LUPIN
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
LUPIN
Mar-19
SHASUN PHARMA/
LUPIN
5-Yr Chart
Click to enlarge
High Rs94986 9.6%   
Low Rs46720 6.3%   
Sales per share (Unadj.) Rs214.2369.5 58.0%  
Earnings per share (Unadj.) Rs5.313.4 39.8%  
Cash flow per share (Unadj.) Rs15.837.4 42.3%  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %1.40-  
Book value per share (Unadj.) Rs53.3303.7 17.6%  
Shares outstanding (eoy) m56.62452.49 12.5%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x0.32.3 14.1%   
Avg P/E ratio x13.163.6 20.6%  
P/CF ratio (eoy) x4.422.8 19.4%  
Price / Book Value ratio x1.32.8 46.6%  
Dividend payout %18.70-   
Avg Mkt Cap Rs m3,958386,064 1.0%   
No. of employees `000NA17.7 0.0%   
Total wages/salary Rs m2,16431,513 6.9%   
Avg. sales/employee Rs ThNM9,453.8-  
Avg. wages/employee Rs ThNM1,782.0-  
Avg. net profit/employee Rs ThNM343.0-  
INCOME DATA
Net Sales Rs m12,127167,182 7.3%  
Other income Rs m2293,640 6.3%   
Total revenues Rs m12,356170,822 7.2%   
Gross profit Rs m1,00928,822 3.5%  
Depreciation Rs m59410,850 5.5%   
Interest Rs m4153,078 13.5%   
Profit before tax Rs m23018,534 1.2%   
Minority Interest Rs m0-89 0.0%   
Prior Period Items Rs m038 -0.8%   
Extraordinary Inc (Exp) Rs m0-3,400 0.0%   
Tax Rs m-739,017 -0.8%   
Profit after tax Rs m3026,066 5.0%  
Gross profit margin %8.317.2 48.3%  
Effective tax rate %-31.748.7 -65.1%   
Net profit margin %2.53.6 68.7%  
BALANCE SHEET DATA
Current assets Rs m6,884138,536 5.0%   
Current liabilities Rs m8,45661,299 13.8%   
Net working cap to sales %-13.046.2 -28.1%  
Current ratio x0.82.3 36.0%  
Inventory Days Days6284 73.6%  
Debtors Days Days108112 95.7%  
Net fixed assets Rs m4,970127,516 3.9%   
Share capital Rs m113905 12.5%   
"Free" reserves Rs m2,875136,517 2.1%   
Net worth Rs m3,020137,422 2.2%   
Long term debt Rs m1,81766,417 2.7%   
Total assets Rs m13,347279,494 4.8%  
Interest coverage x1.67.0 22.1%   
Debt to equity ratio x0.60.5 124.5%  
Sales to assets ratio x0.90.6 151.9%   
Return on assets %5.43.3 164.3%  
Return on equity %10.04.4 226.6%  
Return on capital %13.38.9 149.5%  
Exports to sales %46.40-   
Imports to sales %14.20-   
Exports (fob) Rs m5,622NA-   
Imports (cif) Rs m1,728NA-   
Fx inflow Rs m5,84359,414 9.8%   
Fx outflow Rs m2,17322,282 9.8%   
Net fx Rs m3,66937,132 9.9%   
CASH FLOW
From Operations Rs m39816,660 2.4%  
From Investments Rs m-1,635-32,825 5.0%  
From Financial Activity Rs m1,3097,441 17.6%  
Net Cashflow Rs m71-8,724 -0.8%  

Share Holding

Indian Promoters % 39.2 46.6 84.1%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 3.6 11.3 31.9%  
FIIs % 17.6 31.9 55.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.6 10.1 392.1%  
Shareholders   20,750 98,259 21.1%  
Pledged promoter(s) holding % 12.3 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   PANACEA BIOTECH  DISHMAN PHARMA  J.B.CHEMICALS  NATCO PHARMA  DIVIS LABORATORIES  

Compare SHASUN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 262 Points Lower; Oil & Gas and Banking Stocks Witness Selling(Closing)

Indian share markets witnessed negative trading activity throughout the day and ended lower. At the closing bell, the BSE Sensex stood lower by 262 points (down 0.7%).

Related Views on News

LUPIN Announces Quarterly Results (1QFY20); Net Profit Up 49.3% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, LUPIN has posted a net profit of Rs 3 bn (up 49.3% YoY). Sales on the other hand came in at Rs 44 bn (up 14.6% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN 2018-19 Annual Report Analysis (Annual Result Update)

Jul 18, 2019 | Updated on Jul 18, 2019

Here's an analysis of the annual report of LUPIN for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

LUPIN Announces Quarterly Results (4QFY19); Net Profit Down 1.5% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, LUPIN has posted a net profit of Rs 3 bn (down 1.5% YoY). Sales on the other hand came in at Rs 44 bn (up 77.8% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN LTD Announces Quarterly Results (3QFY19); Net Profit Down 149.7% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, LUPIN LTD has posted a net profit of Rs 2 bn (down 149.7% YoY). Sales on the other hand came in at Rs 45 bn (up 78.0% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

LUPIN LTD Announces Quarterly Results (2QFY19); Net Profit Down 31.1% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, LUPIN LTD has posted a net profit of Rs 3 bn (down 31.1% YoY). Sales on the other hand came in at Rs 40 bn (up 53.1% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA - ALEMBIC PHARMA COMPARISON

COMPARE SHASUN PHARMA WITH

MARKET STATS